Suppr超能文献

疼痛性骨转移。

Painful osseous metastases.

机构信息

Albany Medical College, Department of Anesthesiology, 47 New Scotland Avenue, MC-131, Albany, New York 12208, USA.

出版信息

Pain Physician. 2011 Jul-Aug;14(4):E373-403.

Abstract

Up to 90% of patients with metastatic or advanced stage cancer will experience significant cancer-related pain. Approximately half or more of patients diagnosed with cancer may experience bone pain. It has been estimated that tumor metastases to the skeleton affect roughly 400,000 United States citizens annually. Carcinoma from breast, lung, and prostate cancers account for about 80% of secondary metastatic bone disease. Bone metastases may cause devastating clinical complications associated with dramatic reductions in quality of life, mobility, and independence as well as excruciating refractory pain. Associated complications from osseous metastases also present a substantial economic burden. Currently, there is still a significantly high number of patients suffering with unrelieved pain from osseous metastases. Treatments for painful osseous metastases may not only diminish pain, but may also improve quality of life and independence/mobility, and reduce skeletal morbidity, potential pathologic fractures, spinal cord compression, and other "skeletal-related events." Treatment strategies for painful osseous metastases include systemic analgesics, intrathecal analgesics, glucocorticoids, radiation (external beam radiation, radiopharmaceuticals), ablative techniques (radiofrequency ablation (RFA) and cryoablation), bisphosphonates, chemotherapeutic agents, inhibitors of RANK-RANKL interaction (e.g., denosumab), hormonal therapies, interventional techniques (e.g., kyphoplasty), and surgical approaches. Although the mechanisms underlying the development of bone metastases are not completely understood, there appears to be important bi-directional interactions between the tumor and the bone microenvironment. A greater understanding of the pathophysiology of painful osseous metastases may lead to better and more selective targeted analgesic therapy. Additionally, potential future therapeutic approaches to painful osseous metastases may revolutionize approaches to analgesia for this condition, leading to optimal outcomes with maximal pain relief and minimal adverse effects.

摘要

高达 90%的转移性或晚期癌症患者将经历显著的癌症相关疼痛。大约一半或更多的癌症患者可能会经历骨痛。据估计,肿瘤转移到骨骼影响了大约 40 万美国公民每年。乳腺癌、肺癌和前列腺癌的癌转移约占继发性转移性骨病的 80%。骨转移可导致严重的临床并发症,与生活质量、活动能力和独立性的急剧下降以及剧烈难治性疼痛相关。骨转移的相关并发症也带来了巨大的经济负担。目前,仍有大量患者因骨转移引起的疼痛而无法得到缓解。治疗骨转移引起的疼痛不仅可以减轻疼痛,还可以改善生活质量和独立性/活动能力,减少骨骼发病率、潜在的病理性骨折、脊髓压迫和其他“骨骼相关事件”。治疗骨转移疼痛的策略包括全身镇痛药、鞘内镇痛药、糖皮质激素、放射治疗(外照射、放射性药物)、消融技术(射频消融术 (RFA) 和冷冻消融术)、双膦酸盐、化疗药物、RANK-RANKL 相互作用抑制剂(例如地舒单抗)、激素治疗、介入技术(例如椎体后凸成形术)和手术方法。尽管骨转移的发生机制尚未完全清楚,但肿瘤与骨微环境之间似乎存在着重要的双向相互作用。对骨转移疼痛的病理生理学有更深入的了解,可能会导致更好和更有针对性的镇痛治疗。此外,未来治疗骨转移疼痛的潜在方法可能会彻底改变这种疾病的镇痛方法,从而实现最佳结果,最大程度地缓解疼痛,最小化不良反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验